Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hemal Mehta, Leah N Kim, Thibaud Mathis, Pardis Zalmay, Faruque Ghanchi, Winfried M Amoaku & Laurent Kodjikian. (2020) Trends in Real-World Neovascular AMD Treatment Outcomes in the UK. Clinical Ophthalmology 14, pages 3331-3342.
Read now
Read now
Michael W Stewart. (2015) Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editor. Clinical Ophthalmology 9, pages 1651-1653.
Read now
Read now
Articles from other publishers (5)
Pedro Vanalle Ferrari, Fábio Andre Nanci Izidro Gonçalves, Pier Francesco De Maria, Bruno Torres Herrerias, Carolina Pelegrini Barbosa Gracitelli & Flavio Eduardo Hirai. (2022) How an Integrated Delivery System in Brazil Moved Toward Value-Based Health Care in Ophthalmology. NEJM Catalyst 3:3.
Crossref
Crossref
Daniele Veritti, Valentina Sarao, Valentina Soppelsa, Carla Danese, Jay Chhablani & Paolo Lanzetta. (2022) Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression. Journal of Clinical Medicine 11:2, pages 325.
Crossref
Crossref
Joao Carrasco, Georg-Alexander Pietsch, Marie-Pierre Nicolas, Cecile Koerber, Craig Bennison & Jisu Yoon. (2019) Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. Advances in Therapy 37:1, pages 300-315.
Crossref
Crossref
S Sii, P Aspinall, S Borooah & B Dhillon. (2017) Exploring factors predicting changes in patients’ expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration. Eye 32:4, pages 673-678.
Crossref
Crossref
Ryian Mohamed, Kunal Gadhvi & Evelyn Mensah. (2018) What Effect Does Ethnicity Have on the Response to Ranibizumab in the Treatment of Wet Age-Related Macular Degeneration?. Ophthalmologica 240:3, pages 157-162.
Crossref
Crossref